US regulatory affairs office addresses efficiency question
This article was originally published in Clinica
Executive Summary
The US FDA has begun to re-examine its inspection and reporting practices as a way of better using its stretched resources, according to John Taylor, director of enforcement in the agency's Office of Regulatory Affairs (ORA).